A genetic delivery nanoparticle includes gelatin, a lipidoid, and a genetic molecule payload. The genetic molecule payload can be an RNA, DNA or Crispr system payload. SiRNA is an example payload and can be encapsulated with the gelatin and lipidoid and covalently conjugated to a surface of the nanoparticle. The nanoparticle surface can also include an antibody and PEG conjugated to it. A method for forming genetic delivery nanoparticle includes forming an adduct of gelatin, the lipidoid and a genetic payload; and cross-linking the gelatin to form the genetic delivery nanoparticle. Varying the size of a carbon chain in the lipidoid controls the size of the formed genetic delivery nanoparticle.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A supraparticle includes and can consist of, ultrasmall Au nanoparticles, a stabilizing matrix, and a lipidoid. The supraparticle can advantageously include a labile molecule payload. A method is disclosed to self-assemble the components into ordered multi-unit structures. The method provides a self-limiting assembly process that results in finite-size supraparticles that can store and transport sensitive labile molecule payloads (for example, labile RNAs) and release them selectively upon exposure to biochemical-stimuli within cells when introduced into cells.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Described herein in various embodiments is an adhesive shape memory elastomer (SME) that can adhere to a substrate surface. The SME has an original shape that is set during synthesis of the adhesive SME. The adhesive SME comprises a copolymer network that includes a first monomer residue which is a hydrophilic biocompatible residue with at least one hydrogen bond acceptor, a second monomer residue which has a hydrophobic alkyl side chain, and a third monomer residue that includes at least one hydrogen bond donor. The first, second, and third monomer residue are covalently bonded to one another. The adhesive SME can adhere to the substrate surface via noncovalent interactions between the copolymer network and the substrate surface.
A system for drying a wood product includes a vessel defining a chamber, a condenser for providing heat in the vessel, a compressor that directs pressurized fluid to the condenser, a dehumidifier that recovers thermal energy from the chamber, an energy storage tank that stores heat transfer fluid, an evaporator heat exchanger that transfers thermal energy from the heat transfer fluid to the condenser, a pump that directs the heat transfer fluid from the tank to the dehumidifier and the evaporator heat exchanger, and an oscillating heat pipe (OHP). The OHP has a first portion upstream of the dehumidifier relative to airflow for circulating about the wood product and configured to precool air passing through the first portion to the dehumidifier, and a second portion downstream of the dehumidifier relative to the airflow and configured to preheat air passing from the dehumidifier.
A softened plastic additive, wherein the additive comprises a predetermined quantity of a plastic material and a quantity of a bio-based oil that is heated and mixed with the plastic material to provide a melted plastic and bio-based oil mixture. The quantity of the bio-based oil is determined based on the predetermined quantity of the plastic material.
Disclosed are compositions and methods for treating Duchenne muscular dystrophy. The compositions include a micro-dystrophin having a dystrophin N-terminal domain, a dystrophin R16 domain, a dystrophin R17 domain, a dystrophin R18 domain, a dystrophin R19 domain, and a dystrophin CR domain. The compositions are particularly useful for treating Duchenne muscular dystrophy and for treating cardiac arrhythmia in subjects having or suspected of having Duchenne muscular dystrophy.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Described herein is a food-based contrast agent formulation that contains a concentration of iodine salts encapsulated in a food-grade carrier matrix. The food-based contrast formulation is a free-flowing powder. The food grade carrier matrix includes a fruit juice and a drying aid. In various forms, the food grade carrier matrix also includes a sweetener, an acid. In various forms, and/or a bitter blocker.
A nanomaterial is gold or silver nanoparticle having a nanoparticle surface that consists of one or more of the following extracts from sweet gum leaves: shikimic acid, sweet gum leaf family of Catechins, sweet gum leaf family of Quercetin Sweroside, Afzelechin, p-Coumaric Acid, Epiafzelechin Trimethyl Ether, Myricetin, Naringenin, Phloretin, Procyanidin B1 and related polyphenols, flavonoids and alkaloids. An antiviral/antibacterial agent includes sweet gum mediated silver nanoparticles having a core size and in a concentration having efficacy as an antiviral/antibacterial exceeding a 3 log 10 reduction in viral titer.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Systems, methods, and techniques disclosed and contemplated herein relate to processing high level radioactive waste (HLW). Exemplary techniques are applicable to various fuel types, such as metal/chloride salt HLW streams from pyroprocessing of sodium bonded metallic fast reactor fuel; metal and halide salt HLW from molten salt reactors; and SiC/pyrolytic carbon from mechanically breached TRISO (tri -structural isotropic particle fuel) kernels with oxide fission products (FPs) from reprocessing. Exemplary waste forms are cermets.
Plant seeds with increased protein and methionine content and having a modified expression of a cystathionine γ-synthase (CGS) polypeptide, modified expression of a low methionine content (< about 1.0% methionine) storage protein polypeptide, or modified expression of both are provided. Methods for modifying expression of CGS polypeptides and polynucleotides and low methionine content seed storage polypeptides and polynucleotides include genome editing to modify the MTO1 regulatory region of CGS to create feedback insensitive methionine production and low methionine content polypeptides to create proteome rebalancing toward high methionine content storage protein production, and transformation with recombinant DNA constructs to enhance or suppress expression are disclosed herein.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
Multi-cell electrochemical reaction cell structure for a flow battery or fuel cell having a plurality of cells electrically connected in series or parallel. A first housing has a pair of mating end plates assembled together, each forming a plurality of recesses in which one of the cells is received. One of the end plates has a projection along its perimeter and the other one of the end plates has a groove along its perimeter. The projection is configured to fit within the groove in a mating relationship to seal the housing when the end plates are engaged with each other. A second housing is a tubular shell in which a plurality of tubular flow cell units electrically connected in parallel are housed. Catholyte flows in the tubular flow cell units and anolyte flows in the tubular shell.
H01M 8/0263 - CollectorsSeparators, e.g. bipolar separatorsInterconnectors characterised by the configuration of channels, e.g. by the flow field of the reactant or coolant having meandering or serpentine paths
H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
THE JOHN INNES CENTRE, NORWICH RESEARCH PARK (United Kingdom)
The Curators of the University of Missouri (USA)
Inventor
Meyers, Blake
Belanger, Sebastien
Moore, Graham
Martin, Azahara
Abstract
Disclosed are genetically modified plants in the Pooideae or Bambusoideae subfamilies of plants which exhibit a conditional male-sterile phenotype. Methods of using the plants to produce hybrid seed of a Pooideae or Bambusoideae plant are also disclosed.
A TENS-SLN method is disclosed that avoids causing (or minimizes) muscle contractions in the neck and instead sends a neural code to the brainstem to evoke swallowing, which can be readily detected by routinely used clinical methods such as surface laryngeal EMG, transnasal endoscopy, respiratory plethysmography, and/or laryngeal palpation. Moreover, without electrode position change, alteration of the electrical code can evoke the laryngeal adductor reflex (LAR). Thus, TENS-SLN facilitates assessment and/or treatment of two different airway protective reflexes (swallowing and the LAR), particularly when used in combination with existing methods such as surface laryngeal EMG, transnasal endoscopy, respiratory plethysmography, and/or laryngeal palpation. This method entails applying surface electrodes at a specific location (spot on the anterior neck and delivering a precise electrical code to a precise brainstem region via the superior laryngeal nerve (SLN) branch of the vagus nerve to evoke either swallowing or the LAR (i.e., code-specific response).
A magnetic artificial honeycomb lattice is provided. The magnetic artificial honeycomb lattice includes a multiplicity of connecting elements separated by hexagonal cylindrical pores. The (a) hexagonal cylindrical pores (i) have widths that are substantially uniform; and (ii) are substantially equispaced. The (b) connecting elements includes a magnetic material layer. The connecting elements have: (i) lengths that are substantially uniform; (ii) widths that are substantially uniform; and (iii) a thickness of the magnetic material layer that is substantially uniform and an average thickness. The magnetic artificial honeycomb lattice is configured to receive two input currents and configured to output an output voltage based upon the two input currents.
H03K 19/168 - Logic circuits, i.e. having at least two inputs acting on one outputInverting circuits using specified components using saturable magnetic devices using thin-film devices
B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
H03K 19/16 - Logic circuits, i.e. having at least two inputs acting on one outputInverting circuits using specified components using saturable magnetic devices
H03K 19/21 - EXCLUSIVE-OR circuits, i.e. giving output if input signal exists at only one inputCOINCIDENCE circuits, i.e. giving output only if all input signals are identical
H03K 19/23 - Majority or minority circuits, i.e. giving output having the state of the majority or the minority of the inputs
An electronic computing device for defending files against ransomware. The electronic computing device includes an electronic processor. The electronic processor is configured to receive a selection of a file and convert the file to a protected file having a protected file format including storing data in an alternate data stream in the protected file. The electronic processor is also configured to detect an attempt to access the protected file and block access to the protected file in response to determining that the attempt to access the protected file is unauthorized.
G06F 21/56 - Computer malware detection or handling, e.g. anti-virus arrangements
G06F 21/78 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure storage of data
G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
G06F 21/00 - Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
The present invention provides methods and compositions for decontamination and preservation osteochondral tissue, such as an osteoarticular fracture fragment, meniscus, meniscal tissue, cartilage or other component of a joint or bone tissue fragment autograft, for extended periods of time at room temperature in a tissue storage container or bag. The invention further provides a process for maintaining the sterility of the osteochondral tissue using the apparatus as described.
A signal termination is used within an electronic circuit to terminate signals thereof. The electronic circuit comprises at least two or more layers spaced apart along a vertical axis of the electronic circuit. Furthermore, the electronic circuit comprises a conductor on each layer and a via structure extending along the vertical axis between at least two of the two or more layers and contacting the conductors of two layers, thereby defining a signal path between the layers. Moreover, a termination comprising an absorber sheet is installed on the electronic circuit by covering the via structure with the absorber sheet to absorb a signal traveling along the signal path, thereby terminating the signal at high frequencies.
Methods for measuring crosstalk in an electronic circuit having multiple ports comprises determining two ports of interest of the electronic circuit, in which crosstalk will be measured between. Furthermore, the method includes determining one or more ports of the electronic circuit to be terminated, independent from the ports of interest, so that signals of these ports do not interfere with measuring crosstalk between the two ports of interest. To terminate the ports determined to be terminated, a piece of absorber sheet is used to cover the ports determined to be terminated. Pressure is applied to the piece of absorber sheet such that the piece of absorber sheet makes a good contact and absorbs signals traveling into the ports determined to be terminated, thereby terminating the ports determined to be terminated so that crosstalk between the two ports of interest may be effectively measured.
The present disclosure is broadly concerned with green crosslinkers for use with reservoir temperatures ranging from about 80° C. to about 130° C. These green crosslinkers can crosslink acrylamide-based polymers with crosslinking times ranging from several hours to weeks. The mixture of this green crosslinker with an acrylamide-based polymer solution can be applied to plug reservoirs with fractures and/or matrix channels. Moreover, it can be used in different permeability reservoirs with various channeling problems.
Described herein are shape memory elastomers (SMEs) each comprising a copolymer network structure. The network comprises two distinct polymer components: a first polymer that is a biocompatible, biodegradable shape memory polymer exhibiting hydrophobic properties, and a second polymer that is covalently bonded to the first via the covalent or/and noncovalent interactions. This second polymer is distinguished by its biocompatible, biodegradable, and hydrophilic nature, featuring functional groups with hydrogen bonding capabilities. The network can also incorporate a third polymer, resulting in an SME with multiple shape transition properties. The SMEs described herein have unique potential as biomedical implants. Methods of manufacture are also provided.
The present invention provides methods and compositions for storage and preservation of tissues, for example peripheral nerve allografts, for extended periods of time at room temperature in a sterile tissue culture container or bag.
METHODS OF ALTERING SEED WEIGHT AND SEED OIL CONTENT BY MANIPULATING ALPHA-CARBOXYL-TRANSFERASE (A-CT) ACTIVITY VIA CARBOXYL-TRANSFERASE INTERACTION (CTI) PROTEIN EXPRESSION
A method of altering fatty acid and/or triacylglycerol production in plants and/or algae is provided. The method includes altering activity levels of alpha-carboxyltransferase (α-CT), a catalytic subunit of acetyl-CoA carboxylase (ACCase) by modulating an expression of at least one carboxyltransferase interaction (CTI) gene encoding at least one CTI protein.
Non-human animals and offspring thereof comprising at least one modified chromosomal sequence in a gene encoding a CD163 protein are provided. Animal cells that contain such modified chromosomal sequences are also provided. The animals and cells have increased resistance to pathogens, including porcine reproductive and respiratory syndrome virus (PRRSV). The animals and offspring have chromosomal modifications of a CD163 gene. The invention further relates to methods of breeding to create pathogen-resistant animals and populations of animals made using such methods.
A vehicular adsorbed natural gas (ANG) tank system operates as a mobile, dual gas storage/separation system to enable off-the-natural-gas-grid producers of biogas to use, ship, and process biogas for: (a) onboard delivery to engine of on-demand delivery of methane-rich fuel to an internal-combustion engine; (b) onboard separation of methane from carbon dioxide and extraction of unused fuel as carbon-dioxide-rich commodity, and (c) and large-scale, tractor-trailer shipping of biogas to a biogas upgrading plant and separation of methane from carbon dioxide during discharge at the plant. A mobile tank system on a vehicle comprises vessels filled with porous adsorbent and pressure valves; pressure regulators; pressure/temperature transducers at inlet, outlet, intermediate ports; and an onboard compressor/gas extraction pump. The tank discharging procedure for the separation of biogas into methane and carbon dioxide is such that the concentration of methane in discharged gas is at least 10% greater than in biogas.
F17C 5/06 - Methods or apparatus for filling pressure vessels with liquefied, solidified, or compressed gases for filling with compressed gases
B01D 53/00 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
Aspects disclosed herein relate to compositions comprising novel phosphoinositide 3-kinase (PI3K) inhibitors, and methods of making the novel PI3K inhibitors. Further, various aspects relate to one or more methods of treating a disease using the compositions disclosed herein, including targeted delivery of the novel PI3K inhibitors disclosed herein.
A negative stiffness shell has a convex first position, but can transition or snap to a concave second position under a force applied to the exterior surface of the shell in the convex first position. During the transition, the shell exhibits negative stiffness that permits a large amount of energy to be absorbed. The negative stiffness shell can withstand a high initial force threshold prior to transitioning. In the second, concave position the shell can still resist force. Moreover, it is possible for the shell to revert back to the first, convex position with minimal plastic deformation for subsequent use. The negative stiffness shells can be used collectively and/or in layers to increase the efficiency of the overall negative stiffness shell unit.
The Government of the United States of America, as represented by the Secretary of the Navy (USA)
The Curators of the University of Missouri (USA)
Inventor
Tadjer, Marko J.
Hobart, Karl D.
Gahl, John M.
Brockman, John D.
Abstract
Implementations of the invention provide semiconductor devices including radiation-doped semiconductor junctions, and methods of making the same. In one embodiments, a method includes: providing a set of adjacent semiconductor layers comprising a first semiconductor layer adjacent a second semiconductor layer different from the first semiconductor layer; exposing the set of adjacent semiconductor layers to thermal neutron radiation, thereby causing a first stable isotope of the first semiconductor layer to convert to a second stable isotope, resulting in a doped first semiconductor layer; and exposing the set of adjacent semiconductor layers to thermonuclear irradiation to cause a third stable isotope of the second semiconductor layer to react, resulting in a doped second semiconductor layer; wherein the doped first semiconductor layer and the doped second semiconductor layer form a homojunction or a heterojunction.
H10D 62/85 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group III-V materials, e.g. GaAs
H01L 21/261 - Bombardment with wave or particle radiation to produce a nuclear reaction transmuting chemical elements
H10D 62/60 - Impurity distributions or concentrations
H10D 62/83 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group IV materials, e.g. B-doped Si or undoped Ge
H10D 62/834 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group IV materials, e.g. B-doped Si or undoped Ge further characterised by the dopants
H10D 62/854 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group III-V materials, e.g. GaAs further characterised by the dopants
Detonation nanodiamond nanocarrier platforms to transport quaternary oxime antidotes into the central nervous system have been developed. The nanodiamond-based AChE reactivators contain an organophosphorus poisoning antidote (e.g., a 4-hydroximinopyridinium moiety) bound to a biocompatible linker covalently attached to the nanodiamonds. These functionalized nanodiamonds successfully cross the layer of Madin-Darby Canine Kidney (MDCK) cells, the epithelial cell surrogate BBB model, and demonstrate a measurable dose-independent in vitro reactivation capacity towards human AChE inhibited by toxic organophosphorus compounds.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 35/22 - UrineUrinary tract, e.g. kidney or bladderIntraglomerular mesangial cellsRenal mesenchymal cellsAdrenal gland
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Occupational therapy; Physical therapy; Physical rehabilitation; Health care services in the nature of athletic training; Rehabilitation patient care services
34.
System and method for in-situ measurement of viscoelastic material properties using continuous-wave ultrasound
A system and method for measuring one or more viscoelastic properties of a material under measurement is disclosed. The system includes an emitter-observer transducer pair separated by the material. A signal processing assembly is operable to (i) apply a plurality of excitation signals to the emitter transducer, wherein each of the excitation signals comprises a continuous-wave sinusoidal waveform, (ii) record a plurality of output signals at the observer transducer, wherein each of the output signals corresponds to one of the excitation signals, (iii) analyze the output signals to measure the sound speed of the material, and (iv) determine the viscoelastic properties of the material under measurement by optimizing the parameters of an infinite echo model. The system provides a non-destructive approach for in-situ measurement of viscoelastic material properties.
G01N 11/00 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties
G01N 29/024 - Analysing fluids by measuring propagation velocity or propagation time of acoustic waves
G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
Small anti-inflammatory peptide for blocking NF-κB are disclosed herein. The peptides as well as compositions including the peptides can be administered to inhibit cytokine production and/or inhibit pulmonary inflammation in a subject in need. Particularly embodiments include administration to a subject suffering from coronavirus disease 2019 (COVID-19).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A hybrid (mechanical-capillary-driven) two-phase loop (HTPL) and associated method of use for data centers. The dual-mode HTPL combines a loop thermosiphon (passive mode) and a pumped two-phase loop (active mode). The HTPL will consist of an evaporator (multiple evaporators used for a server rack), a condenser, a pump, and a liquid reservoir. The operation of the HTPL begins with the pumping of a subcooled liquid from the liquid reservoir to the liquid chamber of the evaporator, in which a fraction of the supplied liquid is drawn into the evaporator wick by capillary pumping. Then, the drawn liquid vaporizes in the evaporator wick by the heat input from a heat source (server electronics), and the saturated vapor exits the evaporator and flows through a vapor line to the condenser, where the vapor is condensed and subcooled. Subsequently, the condensate from the condenser flows back to the reservoir.
F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
Crosslinking agents, TRI-1, TRI-2, and TRI-3, and/or a collagen crosslinking mixture comprising two or more of TRI-1, TRI-2 and TRI-3, are presented, as are the syntheses thereof. The collagen crosslinking effects of the mixture of TRI-1, TRI-2, and TRI-3 are significantly enhanced over any of the molecules taken individually. The mixture drastically improves collagen biostability, showing enhanced performance compared to commercially available collagen treatments, and acts quickly, requiring no more than 60 seconds to show inhibition of collagenases. The mixture is also nontoxic and has a slight beige color, which is aesthetically ideal for any treatment that may be visible to others. The collagen crosslinker mixture is furthermore shown to be mixable with commercial dental adhesive without compromising the desired properties of the crosslinkers or the adhesive.
A fiber optic cable system configured for distributed sensing in a brittle installation medium, the fiber optic cable system comprising a fiber optic cable and a plurality of anchors. The fiber optic cable includes a fiber core, a buffer layer, a strength member, and a jacket. These components are secured together at a number of anchoring locations along the fiber optic cable so that they are bonded together at the anchoring locations and un-bonded from each other between the anchoring locations. The anchors are attached to the fiber optic cable at the anchoring locations and are configured to engage the brittle installation medium to affix the fiber optic cable to the brittle installation medium at the anchoring locations.
G01D 5/353 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using optical means, i.e. using infrared, visible or ultraviolet light with attenuation or whole or partial obturation of beams of light the beams of light being detected by photocells influencing the transmission properties of an optical fibre
G02B 6/44 - Mechanical structures for providing tensile strength and external protection for fibres, e.g. optical transmission cables
39.
LYTIC PHAGE WITH HIGH SPECIFICITY TOWARDS PATHOGENIC ESCHERICHIA COLI
Herein are presented methods for incorporating a novel bacteriophage, CAM-21, that exhibits lytic activity against pathogenic E. coli, into food, food packaging, films, and quantum dot-based biosensors. The bacteriophage contains no genes associated with toxins, virulence factors, antibiotic resistance, lysogeny, or allergens. Methods are provided for encapsulating the bacteriophage with proteins and/or carbohydrate materials to enhance stability. Various films in which the bacteriophage are incorporated, and which similarly exhibit suppression of pathogenic E. coli, are also provided. Additionally, when conjugated with N-doped graphene quantum dots, CAM-21 enables biosensor development for E. coli detection in food products through altered photoluminescence emission spectra, and methods for making and using such biosensors are provided.
A structural health monitoring sensor includes a first layer of micromachined planar foil welded to a target structure, the first layer having a cavity and groove formed therein, the groove extending from the first cavity to the exterior of the target structure. The sensor also having second layer of micromachined planar foil welded to the first layer, the second layer having a second cavity corresponding to the first cavity. The sensor also includes dielectric ceramic coating formed within the cavities and grooves to form a film resonator and film waveguide within the target structure. The resulting waveguide forming an opening on the exterior surface of the target structure. The sensor also includes an adapter attached to the exterior surface of the target structure at the waveguide opening and may be wireless.
G01K 5/72 - Measuring temperature based on the expansion or contraction of a material the material being a solid constrained so that expansion or contraction causes a deformation of the solid the solid body being formed of compounded strips or plates, e.g. bimetallic strip specially adapted for indicating or recording with electric transmission means for final indication
G01K 5/66 - Selection of composition of the components of the system
G01L 1/25 - Measuring force or stress, in general using wave or particle radiation, e.g. X-rays, neutrons
The present disclosure is broadly concerned with low toxicity, high-temperature resistant, recrosslinkable, preformed particle gels (HT-RPPGs) for use with reservoir temperatures ranging from about 80°C to about 130°C. These HT-RPPGs include green crosslinkers that can crosslink acrylamide-based polymers with crosslinking times ranging from several hours to days. An additive such as polyvinyl alcohol can be added to the mixture to control swelling ratios for improved thermal stability. The HT-RPPGs can be used to plug reservoirs with fractures and/or matrix channels. Moreover, these HT-RPPGs can be used in different permeability reservoirs with various channeling problems.
A device for placing a glaucoma drainage tube into the sulcus of an eye is provided herein. The device comprises a needle that comprises a hub and a shaft such that the shaft extends from the hub. The shaft comprises a proximal portion extending from the hub and terminating in a first bend, a medial portion extending from the first bend and terminating at a second bend, and a distal portion originating at the second bend and terminating at a tip. The distal portion has an ultra-thin outer wall and an inner diameter defining a lumen. Also provided is a method for using the same, known as the sulcus tube internal needle technique (STINT).
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Health care; Hospital services; Medical clinics; Medical services; Medical services, namely, providing primary and specialty health care services to patients; Medical clinic services; Physical therapy; Preparation of prescriptions by pharmacists; Speech therapy; Telemedicine services; Veterinary services; providing information in the field of healthcare
44.
REAL TIME CONCRETE CURING ASSESSMENT SYSTEM AND METHOD
An apparatus for assessing real-time concrete curing in-situ using a probe includes a sensor base, contacts, a housing, and a processing element. The sensor base has a bottom surface and a port extending into the bottom surface for releasably receiving the probe. The contacts are located in the port for electrically connecting to the probe. The housing is supported on the sensor base and houses the processing element. The processing element is in communication with the contacts and configured to receive a from the contacts and determine a curing phase of the concrete based on the signal from the contacts.
G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
G01R 27/14 - Measuring resistance by measuring current or voltage obtained from a reference source
45.
CPG-FREE CODON-OPTIMIZED HUMAN MICRODYSTROPHIN FOR DUCHENNE MUSCULAR DYSTROPHY GENE THERAPY
The present disclosure is directed to compositions and methods for treating dystrophinopathies. In particular, the present disclosure provides microdystrophins for treating dystrophinopathies by administering compositions encoding microdystrophins.
Marker panels and methods of using the markers in circulating DNA (cirDNA) in maternal blood and/or maternal urine for early detection of fetal growth disorders (FGDs) are disclosed herein. Use of these marker panels will enable accurate prediction of FGDs using a low invasive approach that can be implemented as early as the first gestational trimester.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
Systems and methods are disclosed including a modular blast probe comprising a reusable housing and a custom insert configured to engage and position a top surface of a respective one of a plurality of blast gauges or sensing elements substantially flush with an outer surface of the reusable housing.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
THE CURATORS OF THE UNIVERSITY OF MISSOURI (USA)
Inventor
Andreadis, Stelios
Samuel, Ronel
Baker, Olga
Nam, Kihoon
Abstract
Provided are compositions and methods related to producing salivary gland progenitor cells organoids from human pluripotent stem cells. The methods involve converting pluripotent stem cells stepwise into surface ectoderm (SE), oral ectoderm (OE), and salivary gland epithelial progenitors (SGEPs). Differentiated salivary gland cells which can include differentiated salivary gland acinar cell (SGACs), salivary gland ductal cells (SGDCs) or a combination thereof can be produced from the SGEPs. Organoids that contain salivary gland cells are also provided. The cells and organoids are useful for therapeutic and drug screening purposes.
The present disclosure relates to methods for separating lanthanides and methods for producing non carrier added (n.c.a) 177Lu, for use in particular in nuclear medicine, for diagnostic and/or therapeutic purposes.
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
Alumni association services, namely, promoting the interests of an educational institution and its alumni by developing and maintaining relationships between the institution and its alumni and supporting a culture of philanthropy between the institution and its alumni
Alumni association services, namely, promoting the interests of an educational institution and its alumni by developing and maintaining relationships between the institution and its alumni and supporting a culture of philanthropy between the institution and its alumni
52.
LIGNIN-CONTAINING NANOCELLULOSE AND AG-AU-AG-CL NANOHYBRID AND GREEN FORMATION METHOD
A nanohybrid includes or consisting of Ag—Au—AgCl nanoparticles embedded in lignin-containing nanocellulose (LNC). A green method to form the nanohybrid includes mixing gold and silver metallic precursors in solution with LNC. The solution is maintained for a predetermined time period to permit Ag—Au—AgCl nanohybrid formation via reduction of the metallic precursors by the LNC.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Providing courses of instruction at the university level; Providing courses of instruction at the graduate level; Providing courses of instruction at the post-graduate level; Arranging and conducting college athletic events
55.
PATHOGENIC SENSING, DIFFERENTIATION AND QUANTIFICATION PLATFORMS
A sensor-enabled pathogen identification, differentiation, and quantification system that integrates into supply chains in an end-to-end fashion and is built on a multi-source, multi-sectoral data environment. The system uses portable sensing platforms that are easily integrated at multiple points along a supply chain and which integrate sample analysis and data processing such that all necessary work can be performed on-site and/or via wireless data transfer.
G01N 33/483 - Physical analysis of biological material
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
The present disclosure is generally directed to an artificial exonic barcode system. The exonic barcodes comprise a nucleotide sequence comprising from 5′ to 3′ a 5′ barcode, an intron, and a 3′ barcode, and the disclosure is further directed to a library of these exonic barcodes. The disclosure also describes a method of generating the exonic barcode library and using the library of exonic barcodes in a method of screening for efficiency of transformation and/or expression of one or more genetic constructs in a subject. Primers and probes were also designed for validation of these exonic barcodes and corresponding methods.
The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
58.
BIOACTIVE GLASS COMPOSITIONS AND METHODS OF TREATMENT
Compositions and methods for improving the regeneration of soft tissues as a result of injury or disease are provided. Various compositions are disclosed including a bioactive glass composition derived from calcining a reactant composition. Methods for treating injured or diseased skeletal muscle comprising contacting the injured or diseased skeletal muscle with the bioactive glass composition are also disclosed.
A method of predicting preferred candidate viral strains for vaccine production is described herein. A machine learning framework for predicting preferred candidate viral strains is provided that emphasizes antigen-matching and yield predictions that correlate with features of viral proteins.
A computerized warehouse management system and method of use are disclosed that generates a plan for optimizing the order-picking operations for a collaborative human-robot order-picking system. Specifically, the computerized warehouse management system is flexible and scalable to handle any facility layout, swarm of robots, multiple pickers, and logistical/operational constraints. The platform optimizes four key decisions to improve warehouse operations efficiency, including order batching, batch assignment to robots and pickers, batch sequencing, and collaborative human-robot routing.
A device for measuring a property of a substrate comprises an enclosure, two resonators, and two probes. The substrate has a top surface, and the enclosure defines a cavity for placing the substrate. The resonators extend into the cavity of the enclosure. The probes extend into the cavity, and each of the probes comprises a loop that extends about an axis that is substantially parallel to the top surface of the substrate so that the probes are operable to excite a transverse magnetic mode signal in the cavity.
G01R 27/26 - Measuring inductance or capacitanceMeasuring quality factor, e.g. by using the resonance methodMeasuring loss factorMeasuring dielectric constants
G01R 31/28 - Testing of electronic circuits, e.g. by signal tracer
An elastic wave cloaking lattice-based metamaterial for cloaking an object within a void includes a lattice of connected unit cells arranged to form a void, each unit cell comprising a mass and a plurality of connecting springs, the mass coupled by the plurality of connecting springs to masses in adjacent unit cells, the plurality of connecting springs comprising at least two large springs of a first length and at least two short springs of a second length, the first length greater than the second length, the springs and masses having relational and mechanical characteristics to facilitate elastic wave cloaking in the totality of the lattice. The lattice as a whole has metamaterial properties resulting from the positional relationship and mechanical properties of masses and connecting springs of the unit cells such that the lattice at least partially cloaks an object or material portioned within the void from elastic waves.
F16F 3/02 - Spring units consisting of several springs, e.g. for obtaining a desired spring characteristic with springs made of steel or of other material having low internal friction
B33Y 50/00 - Data acquisition or data processing for additive manufacturing
B33Y 80/00 - Products made by additive manufacturing
63.
VISCOELASTIC PROTECTIVE ARMOR LINERS AND PROTECTIVE ARMOR
Viscoelastic trauma attenuating backings for use in body armor to reduce non-penetrating shockwave injuries. In particular, a protective armor liner comprising a viscoelastic material and graphene nanoplatelets. Also described is a protective armor comprising a protective armor liner disposed therein or disposed thereon, wherein the protective armor liner comprises a viscoelastic material and graphene nanoplatelets.
The instant disclosure provides engineered proteins, constructs for expressing the engineered proteins, and methods of using the engineered proteins and constructs for tethering a protein of interest to an RNA molecule.
A method for synthesizing ultrasmall gelatin nanoparticles. A first desolvation is conducted to produce gelatin strands in a first solution and then setting the pH of the solution to charge and separate the strands. Tripolyphosphate (TPP) is added to the first solution to form gelatin-TPP-gelatin bridges. Second desolvation of the gelatin-TPP-gelatin bridges is conducted in a second solution. The second solution contains an TPP-Ethanol:Acetone mixture in a ratio between 1:1 and 1:5 and TPP between 0.005-0.025 vol % or a Glutaraldehyde-Ethanol:Acetone mixture in a ratio of glutaraldehyde-ethanol:Acetone range of 2.5-12% v/v to produce a colloid of self-assembled gelatin nanoparticles. The method can produce nanomaterial consisting of a plurality of gelatin nanoparticles sized at ˜10 nm. The nanomaterial can encapsulate a drug, metal nanoparticle or contrast agent.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
An in vivo animal retention, data collection and analysis system that comprises an animal retention structure that is structured and operable to temporarily restrain a live animal to be scanned in specific location. The system additionally comprises an animal data acquisition system that is structured and operable to acquire phenotypic data of the animal to be scanned. The system further comprises a data processing system that is structured and operable to execute one or more animal efficiency algorithm that utilizes the acquired phenotypic data to calculate the efficiency of the animal to be scanned.
A treatment composition for the suppression of Type 1 Diabetes (T1D) is described herein, as are methods for using the treatment. Interleukin-4 administrated intrathymically promotes improved central tolerance and minimizes the escape of self-reactive T cells. As a result, negative selection of self-reactive T cells is improved and preservation of a diverse T cell repertoire in the periphery is made possible in patients with or susceptible to T1D.
The present disclosure describes a treatment composition comprising a nanoparticle composition comprising nanoparticles functionalized with surface amine groups and a crosslinking composition comprising genipin. The disclosure also describes a kit comprising the treatment composition, and instructions for using the kit to crosslink the nanoparticles to a tissue graft. The treatment composition and kit can be used to crosslink nanoparticles to a tissue graft, and the resulting tissue graft can be used to replace defective tissue in a subject in need thereof.
The disclosure relates to therapeutic methods comprising administering compounds that can inhibit prolyl hydroxylase and pharmaceutical compositions which comprise the prolyl hydroxylase inhibitors. In particular, the methods and pharmaceutical compositions described herein can be useful for treating a disease or condition of copper metabolism in subjects in need thereof, such as a subject having Wilson disease or Menkes disease.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A unique open-structured graphene material is provided as well as methods of making and using the same. The open-structured graphene may be formed by carbonization of biomass, such as soybeans, followed by an exfoliation process to provide the graphene particles. Unlike pristine graphene, the open-structured graphene of the present technology has an irregular hierarchical pore structure and one or more layers with an undulating shape, which permits it to better facilitate the intercalation of certain doping particles and provides enhanced flexibility to maintain its structure in various end use application (e.g., batteries).
Improved methods and systems for the electrochemical exfoliation of carbonaceous particles to provide graphene are provided. In some aspects, systems according to the present technology may include a plurality of electrodes that may, for example, have an aspect ratio greater than about 3:1. Additionally, a continuous and optionally closed-loop electrochemical exfoliation system may be used. Embodiments of the present technology can achieve graphene yields well in excess of 50% in a more cost- and operationally efficient manner.
Methods of manufacturing oxalic acid from lignocellulosic biomass and use of the manufactured oxalic acid the acidic activator in a new-concept, acid-base cement (ABC) are disclosed.
C12N 1/22 - Processes using, or culture media containing, cellulose or hydrolysates thereof
C04B 28/10 - Lime cements or magnesium oxide cements
C04B 28/28 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing organic polyacids, e.g. polycarboxylate cements
C04B 7/153 - Mixtures thereof with other inorganic cementitious materials or other activators
C04B 28/00 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements
C04B 24/06 - Carboxylic acidsSalts, anhydrides or esters thereof containing hydroxy groups
C04B 24/08 - FatsFatty oilsEster type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
Small, low molecular weight compounds which inhibit the cellular activity of P-type Cu-ATPases, ATP7A and/or ATP7B, and pharmaceutical compositions containing the compounds, are described. Methods of using said compounds in the treatment or prevention of any disease in which copper and/or P1B-type heavy-metal ATPases contribute to disease pathology are also described.
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
Juglans plant named ‘Hickman’ is characterized by high-yield, abundant spur-bearing, medium nut and kernel size, and high kernel percentage. Taken together, ‘Hickman’ produces a high yield of kernels. The cultivar's nuts have a low to moderate rate of defects, and its kernel has good flavor and color quality. ‘Hickman’ is protogynous, with pistillate bloom beginning mid-season and extending about two-weeks and staminate bloom occurring mid-to-late season.
Described herein are luminescent sila- and germafluorenes. Also described herein are methods of making and using sila- and germafluorenes. The position and the type of substituent impact the absorption and emission properties in solution and in the solid-state and subsequently influence the role of sila- and germafluorenes as biosensors.
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
C07F 7/08 - Compounds having one or more C—Si linkages
77.
COMPOSITIONS AND METHODS FOR IMPROVING SEED YIELD OF PLANTS
The disclosure relates to GATA zinc finger and ULTRAPETALA (UTL) genes associated with increased yield of plants. Also disclosed are plants comprising altered expression or activity of the GATA zinc finger or UTL polypeptides along with related methods of increasing yield of plants.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
Described herein are compositions and methods for inducing immune tolerance comprising lipocoacervates loaded with a FasL species and IL-2 protein for controlled release of biologically active FasL and IL-2 over an extended time period.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
79.
A NANOPORE-BASED NUCLEIC ACID CONFORMATION READER FOR SMALL MOLECULE BIOSENSING AND THERAPEUTICAL COMPOUND SCREENING
Provided herein are real-time, label-free methods, systems, apparatuses, and compositions for the detection and characterization of dynamic aptamer-small molecule interactions through the use of nanopore systems that provide accurate detection of time-resolved dynamic nucleic acid conformational variations in response to small molecule binding. The methods, systems, apparatuses, and compositions can quantify specific ligands, elucidate nucleic acid-ligand interactions, and pinpoint the nucleic acid motifs for ligand binding, showing the potential for small molecule biosensing, drug discovery assayed via RNA and DNA conformation changes, and the design of artificial riboswitch effectors in synthetic biology.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
80.
Large-scale carbon-mineralization through oxalatization
The present invention is broadly concerned with mineralization methods that assist in permanent carbon storage. The methods provide a storage mechanism for oxalic acid generated by existing or future-developed carbon capture and conversion methods that convert CO2 to oxalic acid. That oxalic acid can be injected into a subsurface rock formation containing non-carbonate rock to form oxalates or oxalate hydrates. Alternatively, oxalic acid can be mixed with mine tailings, well drilling dirt, crushed rocks, etc., that contain desired non-carbonate rock minerals, to promote mineralization.
Business networking service; On-line business networking services; Association services, namely, promoting the interests of alumni of a university by means of organizing alumni networking events and providing a website featuring alumni and alumni association information
82.
BIOMARKERS FOR EARLY DIAGNOSIS OF CHRONIC HIP DISPLASIA AND METHODS OF USING THE SAME
Methods for predicting canine hip dysplasia (CHD) in an immature canine subject are provided. The methods include the use of concentration profiles of a plurality of polypeptides, including C2C, CTX-I, CTX-II, RANKL, PIICP, COMP, PINP. Also provided are CHD biomarker profiles for predicting or diagnosing CHD in immature or young canines before CHD develops. Diagnostic reagents and kits for the same are also provided.
A noise-reducing surgical aspirator that includes a tube, a handle, having a first end portion, a second end portion, and a first internal fluid conduit, where the first end portion of the handle is attached to the tube in fluid communication, and a surgical aspirator tip having a second internal fluid conduit that is in fluid communication with the first internal fluid conduit of the handle and having a first end portion attached to the second end portion of the handle and having a second end portion having an opening, wherein the second internal fluid conduit of the surgical aspirator tip includes a first inner recessed radius and a second radius with a first fillet located between the first inner recessed radius and the second radius and also includes a third outer radius of the opening and a second fillet located between the second radius and the third outer radius.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A method of producing a four-layer silicon diode, including selecting a first silicon wafer, wherein said first silicon wafer is CZ-grown B-doped with <100> orientation, a resistivity of less than 0.01 Ohm-cm, and an oxygen content of greater than 10 ppma, and then selecting a second silicon wafer, wherein said second silicon wafer is CZ-grown P-doped with <100> orientation, a resistivity of less than 0.005 Ohm-cm, and an oxygen content of greater than 10 ppma, followed by cleaning the respective first and second silicon wafers. The wafers are then HF treated to yield respective first and second cleaned wafers, the first cleaned wafer is positioned into a first furnace and the second cleaned wafer is positioned into a second furnace, wherein the first and second furnaces are not unitary. Next is annealing the respective first and second cleaned wafers in a reducing atmosphere to yield respective first and second respective out-diffused gradient wafers, followed by bonding together respective first and second heat-treated wafers to yield a mated and/or bonded four-layer substrate having a first heavy doped n-type layer, a second gradient doped n-type layer, a third gradient doped p-type layer, and a fourth heavy doped p-type layer.
Genetically modified legume plants comprising a reversibly-sterile phenotype or an improved plant-pollinator phenotype are disclosed. Methods of using the plants to produce hybrid legume seed are also disclosed.
A sensor for detecting virus, including virus particles and/or genetic sequences, and method of fabrication. The sensor includes a field effect transistor (FET) having source and drain electrodes formed on a substrate and a two-dimensional virus sensing transduction material (VSTM) film formed on the FET. The VSTM film is configured to collect a sample collected from a subject and comprises MXene-graphene. The VSTM film has an antibody corresponding to the virus particles to be detected linked to the film. A drain-source current response of the FET is representative of an amount of the virus particles in the sample for indicating an infection.
A variable resistance device includes first and second body elements and a force-generating system disposed therebetween. The force-generating system includes a resiliently deflectable beam extending relative to the first body element and toward the second body element, an interface element, and a cam projecting relative to the second body element and toward the first body element. The cam presents a cam surface. The interface element shifts along the cam surface upon application of a driving force to at least one of the body elements relative to the other and consequent shifting of the body elements relative to each other, resulting in corresponding bending of the beam and consequent generation of a resistance force by the beam. The cam surface presents a profile that varies along a length thereof, such that the resistance force generated by the beam varies irregularly as the interface element moves along the cam surface.
A63B 21/00 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
A63B 21/02 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using resilient force-resisters
A63B 21/04 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using resilient force-resisters attached to static foundation
A diagnostic and therapeutic radiopharmaceutical includes or consisting of a trimeric amino acid structured peptide with a radiolabel. The radiolabel can be [99mTc] [Tc(H2O)3(CO)3]+ or alpha emitting 225Ac. The trimeric amino acid structured peptide can be formed around phosphorus. The trimeric amino acid can be one of a Glycine, Alanine and Arginine amino acids.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Education and entertainment services, namely, providing teaching, training, tutoring and courses of instruction at the post-secondary level; encouraging university athletic programs by organizing and conducting educational programs and activities for athletes; providing a website featuring information about education and the educational experiences of university students and alumni
A storage fluid heater and methods of its use are disclosed for storing, heating, and/or delivering water. The storage fluid heater includes a secondary structure with a pump and heat transfer surface to pump up colder water from the bottom of the tank that has entered via the fluid inlet, heat the water, and release the water at the top of the tank to be withdrawn via the fluid outlet.
Provided herein is an all-in-one-RNA sequencing assay that simultaneously delivers a qualitative characterization and quantitative measurement of selected RNAs. Also provided are various uses of the assay.
Novel compounds and polymer aerogels derived from these compounds are provided. The highly porous, monolithic polymer aerogels are extremely robust having high surface areas, large micropore volumes. and high density of nitrogen and oxygen functionalities. Due to these extraordinary properties, the polymer aerogels possess a high carbon dioxide (CO2) sorption capacity and are highly selective towards CO2 versus other gases, such as H2 and N2. As a result, the polymer aerogels can be used to effectively capture or remove CO2 from the air and/or from flue gases.
C07D 239/74 - QuinazolinesHydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
The present disclosure is generally directed to a bio-ink system that can be used to print cellularized scaffolds for biomedical applications. In certain configurations, the ink has rheological properties suitable for extrusion-based printing techniques and adipose stem cells infused in the ink remain viable seven days after printing. The ink may comprise a mixture of alginate hydrogels, which provide the structural integrity of the printed scaffolds, and gelatin hydrogels, which support the cell proliferation. Borophosphate glass particles are added to the hydrogel mixture where they release Ca-ions that control the viscoelastic properties of the hydrogel before and after printing. Borophosphate glasses described herein promote significantly better ASC viability than previously employed glasses.
B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
The present disclosure relates to methods of diagnosing and treating lung cancer using blood-borne analytes, the levels of which relate to the presence, stage and/or drug-resistant status of lung cancer in an individual. Such analytes are useful for indicating the presence, stage and/or drug-resistant status of lung cancer in an individual and to make treatment decisions for lung cancer patients. The present disclosure also discloses methods of treating lung cancer, some aspects of which include sensitizing lung cancer cells to treatment and decreasing resistance of lung cancer cells to treatment. Also disclosed are kits for practicing methods of the disclosure.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
97.
IMMUNOMODULATION FOR THE LONG TERM PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES AND FOREIGN TISSUE REJECTION
University of Louisville Research Foundation, Inc. (USA)
The Curators of the University of Missouri (USA)
Inventor
Shirwan, Haval
Abstract
Described herein are pharmaceutical compositions, medicaments and methods for providing effective immunomodulation with chimeric proteins including FasL moieties for selective and long-lasting regulation of the immune response.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00 - Drugs for specific purposes, not provided for in groups
98.
THERAPEUTIC NANOPARTICLES FOR SOLID ORGAN IMMUNE ACCEPTANCE
Disclosed are FasL presenting compositions. The compositions may be used to effect immunomodulation in a variety of contexts. The compositions may be used to decrease rates of transplant rejection.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Sloan-Kettering Institute for Cancer Research (USA)
Memorial Hospital for Cancer and Allied Diseases (USA)
Cornell University (USA)
The Curators of the University of Missouri (USA)
Inventor
Bradbury, Michelle S.
Overholtzer, Michael
Aragon, Virginia
Deleon, Gabriel
Wiesner, Ulrich
Quinn, Thomas P.
Mcdevitt, Michael R.
Abstract
Described herein are methods of treating cancer by administering to a subject a composition comprising ultrasmall silica nanoparticles to enhance one or more of the following immunotherapies: chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint blockade antibody therapy (ICB), immune inhibitor therapy (e.g., myeloid-targeting inhibitors). In some embodiments, the compositions are used in combination with external beam radiotherapy.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
100.
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS
The present invention generally relates to genetically modified swine wherein at least one allele of a SIGLEC1 gene has been inactivated and/or at least one allele of a CD163 gene has been inactivated. Genetically modified swine having both alleles of the SIGLEC1 gene and/or both alleles CD163 gene inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSV). Methods for producing such transgenic swine are also provided.
